...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of the American Academy of Child and Adolescent Psychiatry >Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder: a placebo-controlled pilot study.
【24h】

Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder: a placebo-controlled pilot study.

机译：利培酮增强对注意缺陷/多动症的抗药性攻击：安慰剂对照的试验研究。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVE: To evaluate the effects of risperidone augmentation for treatment-resistant aggression in children with attention-deficit/hyperactivity disorder (ADHD). METHOD: Twenty-five children (ages 7-12 years) with attention-deficit/hyperactivity disorder (ADHD) and significant aggressive behaviors were randomized to risperidone or placebo for 4 weeks for this double-blind study. Subjects were already in treatment with a constant dose of psychostimulant medication. The primary efficacy measure was change from baseline in the Children's Aggression Scale-Parent (CAS-P) and -Teacher (CAS-T) total scores. RESULTS: The mean risperidone dose at endpoint was 1.08 mg/day. For the CAS-P total score, a significant difference was found (chi(1)(2) = 4.30, p < .05) with 100% of risperidone subjects improving by more than 30% from baseline to endpoint, whereas only 77% of the placebo group reported a similar response. No differences were found on the CAS-T total score. For the CAS-P and CAS-T, no significant interaction was found between treatment group and time. Rates of adverse events did not differ significantly between groups. CONCLUSIONS: Risperidone treatment appears to be well tolerated and modestly effective when used in combination with psychostimulants for treatment-resistant aggression in children with ADHD.
机译：目的：评价利培酮增强对注意力缺乏/多动症（ADHD）患儿抗药性攻击的作用。方法：本双盲研究将25名注意力缺陷/多动障碍（ADHD）和显着攻击行为的儿童随机分配至利培酮或安慰剂治疗4周。受试者已经接受了恒定剂量的精神刺激药物治疗。主要疗效指标是儿童侵略量表父母（CAS-P）和-教师（CAS-T）总分与基线相比的变化。结果：终点的平均利培酮剂量为1.08 mg / day。对于CAS-P总分，发现有显着差异（chi（1）（2）= 4.30，p <.05），从基线到终点，100％的利培酮受试者改善了30％以上，而只有77％安慰剂组的患者也有类似反应。 CAS-T总分未发现差异。对于CAS-P和CAS-T，治疗组和时间之间没有发现显着的相互作用。两组之间的不良事件发生率没有显着差异。结论：利培酮治疗与精神刺激药联合用于治疗多动症儿童的抗攻击性似乎具有良好的耐受性和适度有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号